WASHINGTON — It’s the literary equivalent of a campaign contribution: a well-placed op-ed piece, endorsing an agency nominee awaiting Senate confirmation. It’s How Washington Works. But few contenders have racked up the sheer number of public tributes as Scott Gottlieb, President Trump’s choice for FDA commissioner, who was confirmed by a Senate vote Tuesday.

Drug company lobbyists, academics with health industry funding, and a flurry of former colleagues have all picked up their pens on behalf of Gottlieb, the 44-year-old physician and former FDA deputy commissioner.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy